Infection,fever, and exogenous and endogenous pyrogens: Some concepts have changed

Journal of Endotoxin Research

Volumn 10, Issue 4, 2004, Pages 201-222

  Dinarello, Charles A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Autoimmune diseases; Cyclooxygenase 2; Cytokines; Prostaglandin E2; Pyrogens

Indexed keywords

BACTERIAL TOXIN; BACTERIUM LIPOPOLYSACCHARIDE; CYCLOOXYGENASE 2; CYTOKINE; CYTOKINE RECEPTOR; ENDOGENOUS PYROGEN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; LIGAND; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROTEIN INHIBITOR; PYROGEN; RECOMBINANT INTERLEUKIN 1; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TOLL LIKE RECEPTOR;

ANTERIOR HYPOTHALAMUS; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BIOSYNTHESIS; BRAIN BLOOD VESSEL; CONCENTRATION RESPONSE; ENZYME SYNTHESIS; FEVER; HOST RESISTANCE; HUMAN; HYPOTHALAMUS; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR SIZE; NONHUMAN; PATHOGENESIS; PROSTAGLANDIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; STRUCTURAL HOMOLOGY; THERMOREGULATION;

AUTOIMMUNE DISEASES; BACTERIAL INFECTIONS; CYCLOOXYGENASE 2; CYTOKINES; DINOPROSTONE; FEVER; HUMANS; ISOENZYMES; LIPOPOLYSACCHARIDES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYROGENS; SIGNAL TRANSDUCTION;

ANIMALIA; BACTERIA (MICROORGANISMS);

EID: 8344261590     PISSN: 09680519     EISSN: None     Source Type: Journal    
DOI: 10.1179/096805104225006129     Document Type: Review

References (198)

1. Beeson PB. Temperature-elevating effect of a substance obtained from polymorphonuclear leucocytes (abstract). J Clin Invest 1948; 27: 524.
2. Atkins E. Pathogenesis of fever. Physiol Rev 1960; 40: 580-646.
3. Poltorak A, He X, Smirnova I et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice mutations in Tlr4 gene. Science 1998; 282: 2085-2088.
4. Gay NJ, Keith FJ. Drosophila Toll and IL-1 receptor. Nature 1991; 351: 355-356.
5. Li S, Ballou LR, Morham SG et al. Cyclooxygenase-2 mediates the febrile response of mice to interleukin-1beta. Brain Res 2001; 910: 163-173.
6. Li S, Goorha S, Ballou LR et al. Intracerebroventricular interleukin-6, macrophage inflammatory protein-1 beta and IL-18 pyrogenic and PGE(2)-mediated? Brain Res 2003; 992: 76-84.
7. Li S, Wang Y, Matsumura K et al. The febrile response to lipopolysaccharide is blocked in cyclooxygenase-2(-/-), but not in cyclooxygenase-1(-/-) mice. Brain Res 1999; 825: 86-94.
8. Chai Z, Gatti S, Toniatti C et al. Interleukin (IL)-6 gene expression in the central nervous system is necessary for fever response to lipopolysaccharide or IL-1 beta: a study on IL-6-deficient mice. J Exp Med 1996; 183: 311-316.
9. Ushikubi F, Segi E, Sugimoto Y et al. Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature 1998; 395: 281-284.
10. Dinarello CA, Gatti S, Bartfai T. Fever: links with an ancient receptor. Curr Biol 1999; 9: R147-R150.
11. Tavares E, Minano FJ. Differential sensitivities of pyrogenic chemokine fevers to cyclooxygenase isozymes antibodies. Brain Res Bull 2002; 59: 181-187.
12. 1 fever. J Physiol (Lond) 1974; 240: 49P-50P.
13. 1 and fever. S Afr Med J 1974; Suppl: 40-41.
14. Sehic E, Blatteis CM. Blockade of lipopolysaccharide-induced fever by subdiaphragmatic vagotomy in guinea pigs. Brain Res 1996; 726: 160-166.
15. Xin L, Blatteis CM. Hypothalamic neuronal responses to interleukin-6 in tissue slices: effects of indomethacin and naloxone. Brain Res Bull 1992; 29: 27-35.
16. Watanabe T, Saiki Y, Sakata Y. The effect of central angiotensin II receptor blockade on interleukin-1beta- and prostaglandin E-induced fevers in rats: possible involvement of brain angiotensin II receptor in fever induction. J Pharmacol Exp Ther 1997; 282: 873-881.
17. Shimizu H, Miyoshi M, Matsumoto K et al. The effect of central injection of angiotensin-converting enzyme inhibitor and the angiotensin type 1 receptor antagonist on the induction by lipopolysaccharide of fever and brain interleukin-1beta response in rats. J Pharmacol Exp Ther 2004; 308: 865-873.
18. Saper CB, Breder CD. The neurologic basis of fever. N Engl J Med 1994; 330: 1880-1886.
19. Saper CB. Neurobiological basis of fever. Ann NY Acad Sci 1998; 856: 90-94.
20. Dinarello CA, Cannon JG, Wolff SM et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 1986; 163: 1433-1450.
21. 2 in brain but not in peripheral blood mononuclear cells. Brain Res 1991; 562: 199-206.
22. Shapiro L, Zhang X-X, Rupp RG et al. Ciliary neurotrophic factor is an endogenous pyrogen. Proc Natl Acad Sci USA 1993; 90: 8614-8618.
23. Dinarello CA, Bernheim HA, Duff GW et al. Mechanisms of fever induced by recombinant human interferon. J Clin Invest 1984; 74: 906-913.
24. Browning JL, Ribolini A. Interferon blocks interleukin 1-induced prostaglandin release from human peripheral monocytes. J Immunol 1987; 138: 2857-2863.
25. Reznikov LL, Kim SH, Westcott JY et al. IL-18 binding protein increases spontaneous and IL-1-induced prostaglandin production via inhibition of IFN-gamma. Proc Natl Acad Sci USA 2000; 97: 2174-2179.
26. Gatti S, Beck J, Fantuzzi G et al. Effect of interleukin-18 on mouse core body temperature. Am J Physiol 2002; 282: R702-R709.
27. Kubota T, Fang J, Brown RA et al. Interleukin-18 promotes sleep in rabbits and rats. Am J Physiol 2001; 281: R828-R838.
28. Lee JK, Kim SH, Lewis EC, Azam T, Reznikov LL, Dinarello CA. Differences in signaling pathways by IL-1β and IL-18. Proc Natl Acad Sci USA 2004; 101: 8815-8820.
29. Mier JW, Vachino G, van der Meer JW et al. Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol 1988; 8: 426-436.
30. Wolff SM. Biological effects of bacterial endotoxins in man. J Infect Dis 1973; 128 (Suppl): 733-758.
31. Greisman SE, Hornick RB. Comparative pyrogenic reactivity of rabbit and man to bacterial endotoxin. Proc Soc Exp Biol Med 1969; 131: 1154-1158.
32. Dinarello CA, Cannon JG, Mier JW et al. Multiple biological activities of human recombinant interleukin 1. J Clin Invest 1986; 77: 1734-1739.
33. Alheim K, Chai Z, Fantuzzi G et al. Hyperresponsive febrile reactions to interleukin (IL) 1alpha and IL-1beta, and altered brain cytokine mRNA and serum cytokine levels, in IL-1beta-deficient mice. Proc Natl Acad Sci USA 1997; 94: 2681-2686.
34. Laughlin MJ, Kirkpatrick G, Sabiston N et al. Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase I clinical trials of colony stimulating factors: G-CSF, GM-CSF, IL-1, IL-2 and M-CSF. Ann Hematol 1993; 67: 267-276.
35. Tewari A, Buhles Jr WC, Starnes Jr HF. Preliminary report: effects of interleukin-1 on platelet counts. Lancet 1990; 336 712-714.
36. Ogilvie AC, Hack CE, Wagstaff J et al. IL-1 beta does not cause neutrophil degranulation but does lead to IL-6, IL-8, and nitrite/nitrate release when used in patients with cancer. J Immunol 1996; 156: 389-394.
37. Nemunaitis J, Ross M, Meisenberg B et al. Phase I study of recombinant human interleukin-1 beta (rhIL-1 beta) in patients with bone marrow failure. Bone Marrow Transplant 1994; 14: 583-588.
38. Crown J, Jakubowski A, Gabrilove J. Interleukin-1: biological effects in human hematopoiesis. Leukoc Lymphoma 1993; 9: 433-440.
39. Smith JW, Longo D, Alford WG et al. The effects of treatment with interleukin-1a on platelet recovery after high-dose carboplatin. N Engl J Med 1993; 328: 756-761.
40. Iizumi T, Sato S, Iiyama T et al. Recombinant human interleukin-1 beta analogue as a regulator of hematopoiesis in patients receiving chemotherapy for urogenital cancers. Cancer 1991; 68 1520-1523.
41. Crown J, Jakubowski A, Kemeny N et al. A phase I trial of recombinant human interleukin-1β alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer. Blood 1991; 78: 1420-1427.
42. Smith JW, Urba WJ, Curti BD et al. The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol 1992; 10: 1141-1152.
43. Tilg H, Trehu E, Shapiro L et al. Induction of circulating soluble tumour necrosis factor receptor and interleukin 1 receptor antagonist following interleukin 1 alpha infusion in humans. Cytokine 1994; 6: 215-219.
44. Bargetzi MJ, Lantz M, Smith CG et al. Interleukin-1 beta induces interleukin-1 receptor antagonist and tumor necrosis factor binding protein in humans. Cancer Res 1993; 53: 4010-4013.
45. van Damme J, Opdenakker G, De Ley M et al. Pyrogenic and haematological effects of the interferon-inducing 22K factor (interleukin-1) from human leukocytes. Clin Exp Immunol 1986; 66 303-311.
46. Zheng H, Fletcher D, Kozak W et al. Resistance to fever induction and impaired acute-phase response in interleukin-1β deficient mice. Immunity 1995; 3: 9-19.
47. Yoshida K, Taga T, Saito M et al. Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci USA 1996; 93: 407-411.
48. Schindler R, Mancilla J, Endres S et al. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 1990; 75: 40-47.
49. Aderka D, Le JM, Vilcek J. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol 1989; 143 3517-3523.
50. 2 in vitro. Exp Cell Res 1994; 215: 51-56.
51. Reznikov LL, Puren AJ, Fantuzzi G et al. Suppression of endotoxin-inducible cytokines in whole blood from human subjects following single dose of recombinant human interleukin-11. J Endotoxin Res 1999; 5: 197-204.
52. Imrie KR, Sheridan B, Colwill R et al. A phase I study of interleukin-6 after autologous bone marrow transplantation for patients with poor prognosis Hodgkin's disease. Leukoc Lymphoma 1997; 25: 555-563.
53. Lazarus HM, Winton EF, Williams SF et al. Phase I multicenter trial of interleukin 6 therapy after autologous bone marrow transplantation in advanced breast cancer. Bone Marrow Transplant 1995; 15: 935-942.
54. Charles P, Elliott MJ, Davis D et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999; 163: 1521-1528.
55. Fisher CJJ, Slotman GJ, Opal SM et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 1994; 22: 12-21.
56. Coceani F, Lees J, Mancilla J et al. Interleukin-6 and tumor necrosis factor in cerebrospinal fluid: changes during pyrogen fever. Brain Res 1993; 612: 165-171.
57. Hauptmann B, Van Damme J, Dayer JM. Modulation of IL-1 inflammatory and immunomodulatory properties by IL-6. Eur Cytokine Netw 1991; 2: 39-46.
58. Chandrasekharan NV, Dai H, Roos KL et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 2002; 99: 13926-13931.
59. Willoughby DA, Moore AR, Colville-Nash PR. COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet 2000; 355: 646-648.
60. Kozak W, Kluger MJ, Soszynski D et al. IL-6 and IL-1β in fever. Studies using cytokine-deficient (knockout) mice. Ann NY Acad Sci 1998; 856: 33-47.
61. Fantuzzi G, Zheng H, Faggioni R et al. Effect of endotoxin in IL-1β-deficient mice. J Immunol 1996; 157: 291-296.
62. Creagan ET, Kovach JS, Moertel CG et al. A phase I clinical trial of recombinant human tumor necrosis factor. Cancer 1988; 62: 2467-2471.
63. Feinberg B, Kurzrock R, Talpaz M et al. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol 1988; 6: 1328-1334.
64. Brown TD, Goodman P, Fleming T et al. A phase II trial of recombinant tumor necrosis factor in patients with adenocarcinoma of the pancreas: a Southwest Oncology Group study. J Immunother 1991; 10: 376-378.
65. Budd GT, Green S, Baker LH et al. A Southwest Oncology Group phase II Trial of recombinant tumor necrosis factor in metastatic breast cancer. Cancer 1991; 68: 1694-1695.
66. Smith JW, Urba WJ, Curti BD et al. Phase II trial of interleukin-1 alpha in combination with indomethacin in melanoma patients (abstract). Proc Am Soc Clin Oncol 1991; 10: 293.
67. Moore MA. Role of interleukin-1 in hematopoiesis. Immunol Res 1989; 8: 165-175.
68. Dinarello CA. Biological basis for interleukin-1 in disease. Blood 1996; 87: 2095-2147.
69. van der Poll T, van Deventer SJ, Hack CE et al. Effects on leukocytes after injection of tumor necrosis factor into healthy humans. Blood 1992; 79: 693-698.
70. Sherman ML, Spriggs DR, Arthur KA et al. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol 1988; 6: 344-350.
71. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-454.
72. Ghezzi P, Saccardo B, Bianchi M. Recombinant tumor necrosis factor depresses cytochrome P450-dependent microsomal drug metabolism in mice. Biochem Biophys Res Commun 1986; 136: 316-321.
73. Tilg H, Trehu E, Atkins MB et al. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994; 83: 113-118.
74. Fattori E, Cappelletti M, Costa P et al. Defective inflammatory response in interleukin 6-deficient mice. J Exp Med 1994; 180: 1243-1250.
75. Di Santo E, Alonzi T, Poli V et al. Differential effects of IL-6 on systemic and central production of TNF: a study with IL-6-deficient mice. Cytokine 1997; 9: 300-306.
76. Blatteis CM. Role of the OVLT in the febrile response to circulating pyrogens. Prog Brain Res 1992; 91: 409-412.
77. Rosendorff C. The pathogenesis of fever: neurochemical aspects. Isr J Med Sci 1976; 12: 960-973.
78. Rosendorff C. Neurochemistry of fever. S Afr J Med Sci 1976; 41: 23-48.
79. Rossi V, Breviario F, Ghezzi P et al. Prostacyclin synthesis induced in vascular cells by interleukin-1. Science 1985; 229: 174-176.
80. Dustin ML, Rothlein R, Bhan AK et al. Induction by IL I and interferon-g: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol 1986; 137: 245-254.
81. Coceani F. Prostaglandins and fever. In: Machowiak P. (ed) Fever: Basic Mechanisms and Management. New York: Raven, 1991; 59-70.
82. Laflamme N, Rivest S. Toll-like receptor 4: the missing link of the cerebral innate immune response triggered by circulating Gram-negative bacterial cell wall components. FASEB J 2001; 15 155-163.
83. Matsumura K, Kaihatsu S, Imai H et al. Cyclooxygenase in the vagal afferents: is it involved in the brain prostaglandin response evoked by lipopolysaccharide? Auton Neurosci 2000; 85 88-92.
84. Simons CT, Kulchitsky VA, Sugimoto N et al. Signaling the brain in systemic inflammation: which vagal branch is involved in fever genesis? Am J Physiol 1998; 275: R63-R68.
85. Szekely M, Balasko M, Kulchitsky VA et al. Multiple neural mechanisms of fever. Auton Neurosci 2000; 85: 78-82.
86. Romanovsky AA, Simons CT, Szekely M et al. The vagus nerve in the thermoregulatory response to systemic inflammation. Am J Physiol 1997; 273: R407-R413.
87. Romanovsky AA, Ivanov AI, Lenczowski MJ et al. Lipopolysaccharide transport from the peritoneal cavity to the blood: is it controlled by the vagus nerve? Auton Neurosci 2000; 85: 133-140.
88. Kapas L, Hansen MK, Chang HY et al. Vagotomy attenuates but does not prevent the somnogenic and febrile effects of lipopolysaccharide in rats. Am J Physiol 1998; 274: R406-R411.
89. Opp MR, Toth LA. Somnogenic and pyrogenic effects of interleukin-1beta and lipopolysaccharide in intact and vagotomized rats. Life Sci 1998; 62: 923-936.
90. Borovikova LV, Ivanova S, Zhang M et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000; 405: 458-462.
91. Wang H, Yu M, Ochani M et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003; 421: 384-388.
92. Ikejima T, Zhang XX, Wen HD et al. IL-1 receptor antagonist reduces IL-1 mediated fever in the rabbit but not LPS or Staphylococcus epidermidis-induced fever (abstract). Clin Res 1991; 39: 462.
93. Dinarello CA, Zhang XX, Wen HD et al. The effect of interleukin-1 receptor antagonist on IL-1, LPS, Staphylococcus epidermidis and tumor necrosis factor fever. In: Bartfai T, Ottoson D. (eds) Neuro-Immunology of Fever. Oxford: Pergammon, 1992; 11-18.
94. Aiura K, Gelfand JA, Wakabayashi G et al. Interleukin-1 (IL-1) receptor antagonist prevents Staphylococcus epidermidis induced hypotension and reduces circulating levels of tumor necrosis factor and IL-1β in rabbits. Infect Immun 1993; 61: 3342-3350.
95. Granowitz EV, Porat R, Mier JW et al. Pharmacokinetics, safety, and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine 1992; 4: 353-360.
96. Antin JH, Weinstein HJ, Guinan EC et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 1994; 84: 1342-1348.
97. Antin JH, Weisdorf D, Neuberg D et al. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 2002; 100: 3479-3482.
98. Rock CS, Coyle SM, Keogh CV et al. Influence of hypercortisolemia on the acute-phase protein response to endotoxin in humans. Surgery 1992; 112: 467-474.
99. Preas 2nd HL, Reda D, Tropea M et al. Effects of recombinant soluble type I interleukin-1 receptor on human inflammatory responses to endotoxin. Blood 1996; 88: 2465-2472.
100. van der Poll T, Jansen J, van Leenen D et al. Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia. J Infect Dis 1993; 168: 955-960.
101. Suffredini AF, Reda D, Banks SM et al. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol 1995; 155: 5038-5045.
102. DeLa Cadena RA, Majluf-Cruz A, Stadnicki A et al. Recombinant tumor necrosis factor receptor p75 fusion protein (TNFR:Fc) alters endotoxin-induced activation of the kinin, fibrinolytic, and coagulation systems in normal humans. Thromb Haemost 1998; 80 114-118.
103. Dinarello CA, Rosenwasser LJ, Wolff SM. Demonstration of a circulating suppressor factor of thymocyte proliferation during endotoxin fever in humans. J Immunol 1981; 127: 2517-2519.
104. Granowitz EV, Porat R, Mier JW et al. Hematological and immunomodulatory effects of an interleukin-1 receptor antagonist coinfusion during low-dose endotoxemia in healthy humans. Blood 1993; 82: 2985-2990.
105. Van Zee KJ, Coyle SM, Calvano SE et al. Influence of IL-1 receptor blockade on the human response to endotoxemia. J Immunol 1995; 154: 1499-1507.
106. Granowitz EV, Santos A, Poutsiaka DD et al. Circulating interleukin-1 receptor antagonist levels during experimental endotoxemia in humans. Lancet 1991; 338: 1423-1424.
107. Moreland LW, Cohen SB, Baumgartner SW et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001; 28: 1238-1244.
108. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-2022.
109. Zou J, Rudwaleit M, Brandt J et al. Up-regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis 2003; 62: 561-564.
110. Fisher CJJ, Dhainaut JF, Opal SM et al. Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double blind, placebo-controlled trial. JAMA 1994; 271: 1836-1843.
111. Opal SM, Fisher CJJ, Dhainaut JF et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 1997; 25: 1115-1124.
112. Abraham E, Wunderink R, Silverman H et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis syndrome. JAMA 1995; 273: 934-941.
113. Abraham E, Anzueto A, Gutierrez G et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998; 351: 929-933.
114. Reinhart K, Wiegand-Lohnert C, Grimminger F et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996; 24: 733-742.
115. Reinhart K, Karzai W. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med 2001; 29: S121-125.
116. Fisher Jr C, Agosti JM, Opal SM et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 1996; 334: 1697-1702.
117. Abraham E, Laterre PF, Garbino J et al. Lenercept (p55 mor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1342 patients. Crit Care Med 2001; 29: 503-510.
118. Abraham E, Glauser MP, Butler T et al. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 1997; 277: 1531-1538.
119. Gershenwald JE, Fong YM, Fahey TJ et al. Interleukin 1 receptor blockade attenuates the host inflammatory response. Proc Natl Acad Sci USA 1990; 87: 4966-4970.
120. Bujak JS, Aptekar RG, Decker JL et al. Juvenile rheumatoid arthritis presenting in the adult as fever of unknown origin. Rheumatology (Oxford) 1973; 52: 431-444.
121. Emmenegger U, Reimers A, Frey U et al. Reactive macrophage activation syndrome: a simple screening strategy and its potential in early treatment initiation. Swiss Med Wkly 2002; 132: 230-236.
122. Choi JH, Suh CH, Lee YM et al. Serum cytokine profiles in patients with adult onset Still's disease. J Rheumatol 2003; 30: 2422-2427.
123. Maeno N, Takei S, Imanaka H et al. Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome. Arthritis Rheum 2004; 50: 1935-1938.
124. Caramaschi P, Biasi D, Carletto A et al. A case of adult onset Still's disease treated with infliximab. Clin Exp Rheumatol 2002; 20: 113.
125. Olivieri I, de Stefano G, Padula A et al. Infliximab in a case of early adult-onset Still's disease. Clin Rheumatol 2003; 22: 369-370.
126. Kraetsch HG, Antoni C, Kalden JR et al. Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences. Ann Rheum Dis 2001; 60 (Suppl 3):55-57.
127. Aeberli D, Oertle S, Mauron H et al. Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med Wkly 2002; 132: 414-422.
128. Kokkinos A, Iliopoulos A, Greka P et al. Successful treatment of refractory adult-onset Still's disease with infliximab. A prospective, non-comparative series of four patients. Clin Rheumatol 2004; 23: 45-49.
129. Cavagna L, Caporali R, Epis O et al. Infliximab in the treatment of adult Still's disease refractory to conventional therapy. Clin Exp Rheumatol 2001; 19: 329-332.
130. Fitzgerald AA, LeClercq SA, Yan A et al. Rapid response to anakinra in patients with refractory adult onset Still's disease. Arthritis Rheum 2004; 46: In press.
131. Rudinskaya A, Trock DH. Successful treatment of a patient with refractory adult-onset Still's disease with anakinra. J Clin Rheumatol 2003; 9: 330-332.
132. Hawkins PN, Lachmann HJ, Aganna E et al. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004; 50: 607-612.
133. Hoffman HM, Mueller JL, Broide DH et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001; 29: 301-305.
134. Hoffman HM, Wanderer AA, Broide DH. Familial cold auto-inflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol 2001; 108: 615-620.
135. Hoffman HM, Gregory SG, Mueller JL et al. Fine structure mapping of CIAS1: identification of an ancestral haplotype and a common FCAS mutation, L353P. Hum Genet 2003; 112: 209-216.
136. Hoffman HM, Wright FA, Broide DH et al. Identification of a locus on chromosome 1q44 for familial cold urticaria. Am J Hum Genet 2000; 66: 1693-1698.
137. Tschopp J, Martinon F, Burns K. NALPs: a novel protein family involved in inflammation. Nat Rev Mol Cell Biol 2003; 4: 95-104.
138. Agostini L, Martinon F, Burns K et al. NALP3 forms an IL-1β processing inflammasome with increased activity in Muckle-Wells auto-inflammatory disorder. Immunity 2004; 20: 319-325.
139. Lovell DJ, Bowyer SL. Treatment of neonatal onset multisystem inflammatory disease (NOMID) with IL-1Ra (anakinra). Arthritis Rheum 2003; 48 (Suppl): S517.
140. Hoffman HM, Rosengren S, Boyle DL et al. Interleukin-1 receptor antagonist prevents cold-associated acute inflammation in familial cold autoinflammatory syndrome. Lancet 2004; In press.
141. Ozen S. Familial Mediterranean fever: revisiting an ancient disease. Eur J Pediatr 2003; 162: 449-454.
142. Chae JJ, Komarow HD, Cheng J et al. Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol Cell 2003; 11: 591-604.
143. Dinarello CA, Wolff SM, Goldfinger SE et al. Colchicine therapy for familial Mediterranean fever - a double blind trial. N Engl J Med 1974; 291: 934-937.
144. Dinarello CA, Chusid MJ, Fauci AS et al. The effect of prophylactic colchicine on leukocytic functions in patients with familial Mediterranean fever. Arthritis Rheum 1976; 19: 618-622.
145. Shoham NG, Centola M, Mansfield E et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci USA 2003; 100: 13501-13506.
146. Ozen S, Bakkaloglu A, Yilmaz E et al. Mutations in the gene for familial Mediterranean fever: do they predispose to inflammation? J Rheumatol 2003; 30: 2014-2018.
147. Drenth JP, Haagsma CJ, van der Meer JW. Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group. Medicine (Baltimore) 1994; 73: 133-144.
148. Drenth JP, Goertz J, Daha MR et al. Immunoglobulin D enhances the release of tumor necrosis factor-alpha, and interleukin-1 beta as well as interleukin-1 receptor antagonist from human mononuclear cells. Immunology 1996; 88: 355-362.
149. Takada K, Aksentijevich I, Mahadevan V et al. Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 2003; 48: 2645-2651.
150. Simon A, Drewe E, van der Meer JW et al. Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther 2004; 75: 476-483.
151. McDermott MF, Aksentijevich I, Galon J et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97: 133-144.
152. Galon J, Aksentijevich I, McDermott MF, et al. TNFRSF1A mutations and autoinflammatory syndromes. Curr Opin Immunol 2000; 12: 479-486.
153. Shapiro L, Clark BD, Orencole SF et al. Detection of tumor necrosis factor soluble receptor p55 in blood samples from healthy and endotoxemic humans. J Infect Dis 1993; 167: 1344-1350.
154. Ulevitch RJ, Tobias PS. Recognition of endotoxin by cells leading to transmembrane signaling. Curr Opin Immunol 1994; 6 125-130.
155. Atkins E. Fever: the old and the new. J Infect Dis 1984; 149: 339-348.
156. Murphy PA, Chesney PJ, Wood Jr WB. Further purification of rabbit leukocyte pyrogen. J Lab Clin Med 1974; 83: 310-322.
157. Root RK, Nordlund JJ, Wolff SM. Factors affecting the quantitative production and assay of human leukocytic pyrogen. J Lab Clin Med 1970; 75: 679-693.
158. Bodel P. Studies on the mechanism of endogenous pyrogen production. I. Investigation of new protein synthesis in stimulated human blood leucocytes. Yale J Biol Med 1970; 43: 145-163.
159. Nordlund JJ, Root RK, Wolff SM. Studies on the origin of human leukocytic pyrogen. J Exp Med 1970; 131: 727-743.
160. Bodel P, Atkins E. Release of endogenous pyrogen by human monocytes. N Engl J Med 1967; 276: 1002-1008.
161. Bodel P, Ralph P, Wenc K et al. Endogenous pyrogen production by Hodgkin's disease and human histiocytic lymphoma cell lines in vivo. J Clin Invest 1980; 65: 514-518.
162. Bodel PT, Hollingsworth JW. Pyrogen release from human synovial exudate cells. Br J Exp Pathol 1968; 49: 11-19.
163. Bodel P. Colchicine stimulation of pyrogen production by human blood leukocytes. J Exp Med 1976; 143: 1015-1026.
164. Manie S, Schmid-Alliana A, Kubar J et al. Disruption of microtubule network in human monocytes induces expression of interleukin-1 but not that of interleukin-6 nor tumor necrosis factor-alpha. Involvement of protein kinase A stimulation. J Biol Chem 1993; 268: 13675-13681.
165. Elin RJ, Wolff SM. Biology of endotoxin. Annu Rev Med 1976; 27: 127-141.
166. Revhaug A, Michie HR, Manson JM et al. Inhibition of cyclooxygenase attenuates the metabolic response to endotoxin in humans. Arch Surg 1988; 123: 162-170.
167. Michie HR, Manogue KR, Spriggs DR et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988; 318: 1481-1486.
168. Michel M, Duvoux C, Hezode C et al. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease. J Rheumatol 2003; 30: 1624-1625.
169. Kimball HR, Melmon ML, Wolff SM. Endotoxin-induced kinin production in man. Proc Soc Exp Biol Med 1972; 139: 1078-1082.
170. Dale DC, Fauci AS, Guerry DI et al. Comparison of agents producing a neutrophilic leukocytosis in man. Hydrocortisone, prednisone, endotoxin, and etiocholanolone. J Clin Invest 1975; 56: 808-813.
171. Dinarello CA, Goldin NP, Wolff SM. Demonstration and characterization of two distinct human leukocytic pyrogens. J Exp Med 1974; 139: 1369-1381.
172. Murphy PA, Cebula TA, Levin J et al. Rabbit macrophages secrete two biochemically and immunologically distinct endogenous pyrogens. Infect Immun 1981; 34: 177-183.
173. Hanson DF, Murphy PA. Demonstration of interleukin 1 activity in apparently homogeneous specimens of the pI 5 form of rabbit endogenous pyrogen. Infect Immun 1984; 45: 483-490.
174. Auron PE, Webb AC, Rosenwasser LJ et al. Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci USA 1984; 81: 7907-7911.
175. Lomedico PT, Gubler R, Hellmann CP et al. Cloning and expression of murine interleukin-1 cDNA in Escherichia coli. Nature 1984; 312: 458-462.
176. Coeshott C, Ohnemus C, Pilyavskaya A et al. Converting enzyme-independent release of TNF-α and IL-1β from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase-3. Proc Natl Acad Sci USA 1999; 96: 6261-6266.
177. Dinarello CA, Renfer L, Wolff SM. Human leukocytic pyrogen: purification and development of a radioimmunoassay. Proc Natl Acad Sci USA 1977; 74: 4624-4627.
178. Merriman CR, Pulliam LA, Kampschmidt RF. Comparison of leukocytic pyrogen and leukocytic endogenous mediator. Proc Soc Exp Biol Med 1977; 154: 224-227.
179. Kampschmidt RF. Leukocytic endogenous mediator/endogenous pyrogen. In: Powanda MC, Canonico PG. (eds) The Physiologic and Metabolic Responses of the Host. Amsterdam: Elsevier, 1981; 55-74.
180. McAdam KPWJ, Dinarello CA. Induction of serum amyloid A synthesis by human leukocytic pyrogen. In: Agarwal MK. (ed) Bacterial Endotoxins and Host Response. Amsterdam: Elsevier, 1980; 167-178.
181. Gery I, Waksman BH. Potentiation of the T-lymphocyte response to mitogens. II. The cellular source of potentiating mediator(s). J Exp Med 1972; 136: 143-155.
182. Rosenwasser LJ, Dinarello, CA, Rosenthal AS. Adherent cell function in murine T-lymphocyte antigen recognition. IV. Enhancement of murine T-cell antigen recognition by human leukocytic pyrogen. J Exp Med 1979; 150: 709-714.
183. Dayer JM, Graham R, Russell G, et al. Collagenase production by rheumatoid synovial cells: stimulation by a human lymphocyte factor. Science 1977; 195: 181-183.
184. Dinarello CA. Interleukin-1. Rev Infect Dis 1984; 6 51-95.
185. Westphal O, Luderitz O, Rietschel ET et al. Bacterial lipopolysaccharide and its lipid A component: some historical and some current aspects. Biochem Soc Trans 1981; 9: 191-195.
186. Rietschel ET, Kim YB, Watson DW et al. Pyrogenicity and immunogenicity of lipid A complexed with bovine serum albumin or human serum albumin. Infect Immun 1973; 8: 173-177.
187. Rietschel ET, Schade U, Jensen M et al. Bacterial endotoxins: chemical structure, biological activity and role in septicemia. Scand J Infect Dis Suppl 1982; 31: 8-21.
188. Luderitz O, Simmons DA, Westphal G. The immunochemistry of Salmonella chemotype VI O-antigens. The structure of oligosaccharides from Salmonella group U (o-43) lipopolysaccharides. Biochem J 1965; 97: 820-826.
189. Galanos C, Luderitz O, Westphal O. Preparation and properties of antisera against the lipid-A component of bacterial lipopolysaccharides. Eur J Biochem 1971; 24: 116-122.
190. Cooper KE, Veale WL, Pittman QJ. Metabolic and other aspects of fever. Isr J Med Sci 1976; 12: 955-959.
191. Pittman QJ, Veale WL, Cooper KE. Observations on the effect of salicylate in fever and the regulation of body temperature against cold. Can J Physiol Pharmacol 1976; 54: 101-106.
192. Granowitz EV, Porat R, Gelfand JA et al. Administration of low-dose endotoxin to healthy humans increases C5a binding to circulating neutrophils. J Infect Dis 1994; 169: 480-482.
193. Michie HR, Spriggs DR, Manogue KR et al. Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery 1988; 104: 280-286.
194. Greisman SE, Hornick RB. The nature of endotoxin tolerance. Trans Am Clin Climatol Assoc 1975; 86: 43-50.
195. Greisman SE, Hornick RB. Mechanisms of endotoxin tolerance with special reference to man. J Infect Dis 1973; 128: 265-276.
196. Mickenberg ID, Snyderman R, Root RK et al. The relationship of complement consumption to immune fever. J Immunol 1971; 107: 1466-1476.
197. Mickenberg ID, Snyderman R, Root RK et al. Immune fever in the rabbit: responses of the hematologic and complement systems. J Immunol 1971; 107: 1457-1465.
198. Root RK, Wolff SM. Pathogenetic mechanisms in experimental immune fever. J Exp Med 1968; 128: 309-323.